Tumor-Inhibition Effect of Levetiracetam in Combination with Temozolomide in Glioblastoma Cells
| Project/Area Number |
26462188
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | Nara Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
本山 靖 奈良県立医科大学, 医学部, 准教授 (30405386)
松田 良介 奈良県立医科大学, 医学部, 助教 (60453164)
田村 健太郎 奈良県立医科大学, 医学部, 助教 (00423913)
竹島 靖浩 奈良県立医科大学, 医学部, 助教 (60510203)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2015: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | glioblastoma / levetiracetam / temozolomide / premature senescence / ｌｅｖｅｔｉｒａｃｅｔａｍ / γδT cell |
|---|
| Outline of Final Research Achievements |
Glioblastoma (GBM) is a malignant brain tumor with a poor prognosis. The standard postoperative chemotherapy is temozolomide (TMZ), which does not greatly improve survival. Antiepileptic drug levetiracetam (LEV) is commonly prescribed, but the therapeutic advantages of the LEV and TMZ combination remain poorly understood.
We evaluated cell proliferation and premature senescence after single and combined treatments of TMZ and LEV in several GBM cell lines that differ in TMZ sensitivity. Both LEV and TMZ reduced cell proliferation in a dose-dependent manner in A172 cells. A senescent-like phenotype was induced by both TMZ and LEV. Overall, there was a greater effect following combined treatment compared to the monotherapy groups. Thus, LEV appears to have a tumor-suppressive effect and induces cellular senescence, and combined treatment of LEV and TMZ enhanced these effects. LEV use in GBM treatment may allow for reduction of the TMZ dose to enhance the clinical efficacy of TMZ.
|
Report
(4 results)
Research Products
(29 results)
-
-
[Journal Article] Antitumor effects of minodronate, a third-generation nitrogen-containing bisphosphonate, in synergy with γδT cells in human glioblastoma in vitro and in vivo.2016
Author(s)
Nakazawa T, Nakamura M, Matsuda R, Nishimura F, Park YS, Motoyama Y, Hironaka Y, Nakagawa I, Yokota H, Yamada S, Tamura K, Takeshima Y, Omoto K, Tanaka Y, Ouji Y, Yoshikawa M, Tsujimura T, Nakase H.
-
Journal Title
J Neurooncol
Volume: 129
Issue: 2
Pages: 231-241
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Tumor-Inhibition Effect of Levetiracetam in Combination with Temozolomide in Glioblastoma Cells2016
Author(s)
Marutani A., Nakamura M., Nishimura F., Nakazawa T., Matsuda R., Hironaka Y., Nakagawa I., Tamura K., Takeshima Y., Motoyama Y., Park Y-S, Ouji Y., Yoshikawa M., Nakase H.
-
Journal Title
Neurochemical Journal
Volume: Volume10, No4
Issue: 1
Pages: 333-339
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] 膠芽腫細胞株におけるミノドロン酸の抗腫瘍効果の検討2014
Author(s)
中村光利, 中澤務, 松田良介, 朴永銖, 本山靖, 新靖史, 弘中康雄, 中川一郎, 西村文彦, 田村健太郎, 竹島靖浩, 丸谷明子, 中瀬裕之
Organizer
第32回日本脳腫瘍学会学術集会
Place of Presentation
東京
Year and Date
2014-11-30 – 2014-12-02
Related Report
-
[Presentation] 末梢血由来細胞傷害性γδT細胞による膠芽腫治療法の開発.2014
Author(s)
丸谷明子, 中村光利, 中澤務, 朴永銖, 本山靖, 新靖史, 弘中康雄, 中川一郎, 西村文彦, 松田良介, 田村健太郎, 竹島靖浩, 辻村貴弘, 中瀬裕之
Organizer
第73回日本脳神経外科学会学術総会
Place of Presentation
東京
Year and Date
2014-10-09 – 2014-10-11
Related Report
-
-
-
-
-
-
[Book] 日本臨床2016
Author(s)
中瀬裕之,本山靖,山田修一
Total Pages
6
Publisher
日本臨牀社
Related Report
-
-
